Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Panel: Targeted Radiotherapy and the Impact on IO

  • Broadcast in Science
Pharma Talk Radio

Pharma Talk Radio

Featured Host
×  

Follow This Show

If you liked this show, you should follow Pharma Talk Radio.
h:548881
s:12189616
archived
Play
  • Host
  • What is the impact of targeted radiotherapy on the immune system?
  • What are the implications for combination IO?
  • Current approaches and future direction

Moderated by:
Michael Groaning, PhD, Global Medical Affairs Lead, Genitourinary, Amgen

Panelists:

  • Charles Glaus, PhD, Sr Director, Radiomics & Radiology Biomarkers, Bayer US-Pharmaceuticals
  • Jeff Legos, PhD, MBA, EVP, Global Head of Oncology & Hematology Development , Novartis
  • Matthew Silva, PhD, CEO , Invicro
  • Ohad Ilovich, PhD, Senior Director, Translational Sciences, Curie Therapeutics

Learn more about the IO360° Summit at www.io360summit.com

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled